Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P355 Acceptability of treatment regimen in inflammatory bowel disease: Results from a prospective nationwide study (ACCEPT2)

ECCO'20 Vienna

Year: 2020
Authors:

A. Buisson1, M. Fumery2, M. Serrero3, L. Orsat1, S. Nancey4, P. Rivière5, R. Altwegg6, L. Peyrin-Biroulet7, M. Nachury8, X. Hébuterne9, C. Gilletta10, M. Flamant11, S. Viennot12, G. Bouguen13, A. Amiot14, S. Mathieu15, L. Vuitton16, L. Plastaras17, A. Bourreille18, L. Caillo19, F. Goutorbe20, M. Fumery21, G. Pineton de Chambrun6, A. Attar22, X. Roblin23, B. Pereira24, B. Pariente8

1CHU Estaing, Department of Digestive and Hepatobiliary Medicine, Department of Gastroenterology, Clermont-Ferrand, France, 2CHU Amiens, Gastroenterology, Amiens, France, 3CHU Marseille, Gastroenterology, Marseille, France, 4CHU Lyon-Sud, Gastroenterology, Lyon, France, 5CHU Bordeaux, Gastroenterology, Bordeaux, France, 6CHU Montpellier, Gastroenterology, Montpellier, France, 7CHU Nancy, Gastroenterology, Nancy, France, 8CHU Lille, Gastroenterology, Lille, France, 9CHU Nice, Gastroenterology, Nice, France, 10CHU Toulouse, Gastroenterology, Toulouse, France, 11Private practice, Gastroenterology, Nantes, France, 12CHU Caen, Gastroenterology, Caen, France, 13CHU Rennes, Gastroenterology, Rennes, France, 14CHU Créteil, Gastroenterology, Créteil, France, 15Private practice- Pole Sante Republique ELSAN, Gastroenterology, Clermont-ferrand, France, 16CHU Besançon, Gastroenterology, Besançon, France, 17CH Colmar, Gastroenterology, Clermont-Ferrand, France, 18CHU Nantes, Gastroenterology, Nantes, France, 19CHU Nîmes, Gastroenterology, Nîmes, France, 20CH Bayonne, Gastroenterology, Bayonne, France, 21Private practice, Gastroenterology, Amiens, France, 22Private practice, Gastroenterology, Paris, France, 23CHU St Etienne, Gastroenterology, St-Etienne, France, 24CHU, Biostatistics unit, Clermont-Ferrand, France

P356 Infectious events in patients with inflammatory bowel disease: The impact of immunomodulators and tumour necrosis factor antagonist therapy

ECCO'20 Vienna

Year: 2020
Authors:

P. Andersson, P. Karling

Department of Public Health and Clinical Medicine, Umeå University, Medicine, Umeå, Sweden

P357 Importance of stool drug monitoring in anti-TNF-treated patients

ECCO'20 Vienna

Year: 2020
Authors:

P. Bacsur1, K. Szántó1, T. Madácsy1, D. Kata1, T. Ferenci2, M. Rutka1, A. Bálint1, R. Bor1, A. Fábián1, Á. Milassin1, G. Elekes3, Z. Szepes1, F. Nagy1, I. Földesi3, J. Maléth1, K. Farkas1, T. Molnár1

1First Department of Medicine, University of Szeged, Szeged, Hungary, 2Physiological Controls Research Center, Óbuda University,Budapest, Hungary, 3Department of Laboratory Medicine, University of Szeged, Szeged, Hungary

P358 Predictors of response to faecal microbiota transplantation in patients with active ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

A. Singh1, A. Sood1, V. Midha2, R. Mahajan1, N. Bansal3, K. Kaur4, D. Singh3

1Department of Gastroenterology, Dayanand Medical College and Hospital - Ludhiana, Ludhiana, India, 2Department of Medicine, Dayanand Medical College and Hospital - Ludhiana, Ludhiana, India, 3Research and Development Centre, Dayanand Medical College and Hospital - Ludhiana, Ludhiana, India, 4Department of Pharmacology, Dayanand Medical College and Hospital - Ludhiana, Ludhiana, India

P359 Platelet-rich stroma injection (PRS) as a novel surgical treatment of refractory perianal fistulas in Crohn’s disease: A pilot study

ECCO'20 Vienna

Year: 2020
Authors:

J. Arkenbosch1, O. van Ruler2, R.S. Dwarkasing3, W.R. Schouten2, A.C. de Vries1, E.J.R. de Graaf2, C.J. van der Woude1

1Department of Gastroenterology, Erasmus MC, Rotterdam, The Netherlands, 2Department of Surgery, IJsselland Hospital, Capelle a/d IJssel, The Netherlands, 3Department of Radiology, Erasmus MC, Rotterdam, The Netherlands

P360 Safety and clinical efficacy of double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicentre study

ECCO'20 Vienna

Year: 2020
Authors:

S. Mazza1, A. Fascì1, V. Casini2, C. Ricci3, F. Munari3, L. Pirola4, C. Girelli5, G. Lupinacci6, L. Pastorelli7, F. Cavallaro7, N. Piazza O’Sed7, L. Ferraris8, A. Colucci8, A. Amato9, V. Maurizio1,10, G. Fiorino11, F. Caprioli1,10

1Fondazione IRCCS Cà Granda- Ospedale Policlinico di Milano, Gastroenterology and Endoscopy Unit, Milan, Italy, 2ASST Bergamo Est – Ospedale di Seriate, Unità Operativa di Gastroenterologia, Seriate, Italy, 3ASST degli Spedali Civili di Brescia, Unità Operativa di Gastroenterologia, Brescia, Italy, 4ASST Monza − Ospedale San Gerardo di Monza, Unità Operativa di Gastroenterologia, Monza, Italy, 5ASST Valle Olona – Ospedale di Busto Arsizio, Unità Operativa di Medicina I, Busto Arsizio, Italy, 6ASST Crema – Ospedale Maggiore di Crema, Unità Operativa di Gastroenterologia, Crema, Italy, 7Policlinico San Donato, Unità Operativa di Gastroenterologia, San Donato Milanese, Italy, 8ASST Valle Olona – Ospedale di Gallarate, Unità Operativa di Gastroenterologia, Gallarate, Italy, 9Ospedale Valduce di Como, Unità Operativa di Gastroenterologia, Como, Italy, 10University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy, 11Istituto Clinico Humanitas, IBD Center, Rozzano, Italy

P361 The effect of immunomodulators and other factors on the persistence of biological agents for Crohn’s disease and ulcerative colitis: data from the Australian population-based registry

ECCO'20 Vienna

Year: 2020
Authors:

Y. Ko1,2, S. Paramsothy1,2, R. Leong1,2

1Gastroenterology and Liver Services, Concord Repatriation General Hospital, Sydney, Australia, 2Concord Clinical School, University of Sydney, Sydney, Australia

P362 Prospective study of phArmaCokinetics of InFliximab during induction in patients with Crohn’s disease and ulcerative colitis (PACIFIC)

ECCO'20 Vienna

Year: 2020
Authors:

C. Liefferinckx1, P. Bossuyt2, D. Thomas3, J.F. Rahier4, E. Louis5, F. Baert6, P. Dewint7,8, L. Pouillon2, G. Lambrecht9, S. Vermeire10, D. Franchimont1, of Belgian Inflammatory Bowel Disease Research and Development (BIRD)

1Department of Gastroenterology, Hôpital Erasme, Brussels, Belgium, 2Department of Gastroenterology, Imelda General Hospital, Bonheiden, Belgium, 3Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium, 4Department of Gastroenterology, CHU UCL Namur, Yvoir, Belgium, 5Department of Gastroenterology, Centre Hospitalier Universitaire Sart-Tilman, Liège, Belgium, 6Department of Gastroenterology, AZ Delta, Roeselare, Belgium, 7Department of Gastroenterology, AZ Maria Middelares, Gent, Belgium, 8Department of Gastroenterology, UZ Antwerp, Antwerp, Belgium, 9Department of Gastroenterology, AZ Damian, Oostende, Belgium, 10Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium

P363 Moderate endurance and muscle training are safe to perform for patients with quiescent or mild active Crohn’s disease and increases their strength

ECCO'20 Vienna

Year: 2020
Authors:

W.A. Seeger1,2, J. Thieringer1, P. Esters1, B. Allmendinger1, H. Schulze1, A. Dignass1

1Department of Medicine I, Agaplesion Markus Hospital, Goethe-University, Frankfurt, Germany, 2Department of Gastroenterology, Infectious Diseases, Rheumatology, Charité -Universitätsmedizin, Berlin, Germany

P364 New insights into the molecular mechanisms of thalidomide in paediatric inflammatory bowel disease patients

ECCO'20 Vienna

Year: 2020
Authors:

M. Lucafò1, M. Bramuzzo2, L. Pugnetti3, M. Gerdol4, S. Greco4, M. Paci5, D. Curci6, M. Nonnis4, S. Renzo5, P. Lionetti5, A. Tommasini1, G. Decorti7, G. Stocco4

1Institute for Maternal Health - IRCCS ‘Burlo Garofolo’, Advanced in Translational Diagnostics Laboratory, Trieste, Italy, 2Institute for Maternal Health - IRCCS ‘Burlo Garofolo’, Gastroenterology- Digestive Endoscopy and Clinical Nutrition Unit, Trieste, Italy, 3Department of Medical-Surgical and Health Sciences, PhD School in Science of Reproduction and Development- University of Trieste- Trieste- Italy, Trieste, Italy, 4Department of Life Sciences, University of Trieste - Trieste - Italy, Trieste, Italy, 5Gastroenterology Unit, Anna Meyer Children’s Hospital -Florence- Italy, Florence, Italy, 6Department of Medical-Surgical and Health Sciences, PhD School in Science of Reproduction and Development, University of Trieste - Trieste - Italy, Trieste, Italy, 7Department of Medical-Surgical and Health Sciences, University of Trieste - Trieste - Italy, Trieste, Italy

P365 Identification of predictive factors of AZA/6-MP treatment outcome in paediatric luminal Crohn’s disease: a multicentre study of the paediatric IBD Porto group of ESPGHAN

ECCO'20 Vienna

Year: 2020
Authors:

T. LERCHOVA1, O. Hradsky1, M. Kulich2, G. Veres3, J.A. Dias4, M. Sladek5, S. Kolacek6, S. Van Biervliet7, J. Melek8, D. Serban9, K. Winther10, T. de Meij11, J. Schwarz12, K.L. Kolho13, J.C. Escher14, J. Bronsky1

1Department of Paediatrics, 2nd Faculty of Medicine- Charles University and Motol University Hospital, Prague, Czech Republic, 2Department of Probability and Mathematical Statistics, School of Mathematics- Charles University, Prague, Czech Republic, 3Pediatric Institute-Clinic, University of Debrecen, Debrecen, Hungary, 4Department of Paediatrics, Hospital de Sao Joao, Porto, Portugal, 5Department of Pediatrics- Gastroenterology and Nutrition, Polish-American Children’s Hospital- Jagiellonian University Medical College, Cracow, Poland, 6Department of Paediatrics, Children’s Hospital Zagreb Faculty of Medicine, Zagreb, Croatia, 7Department of Pediatrics and Medical Genetics, Ghent University- Ghent University Hospital, Ghent, Belgium, 8Department of Paediatrics, Charles University Teaching Hospital, Hradec Kralove, Czech Republic, 9Department of Gastroenterology, 2nd Clinic of Pediatrics- ‘Iuliu Hatieganu’ University of Medicine and Pharmacy- Emergency Clinical Hospital for Children, Cluj-Napoca, Romania, 10Department of Paediatrics, Hvidovre Hospital, Copenhagen, Denmark, 11Department of Paediatrics, Amsterdam UMC- Location VUMC, Amsterdam, The Netherlands, 12Department of Paediatrics, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic, 13Department of Gastroenterology, Children’s Hospital and University of Helsinki, Helsinki, Finland, 14Department of Gastroenterology, Erasmus MC−Sophia Children’s Hospital, Rotterdam, The Netherlands

P366 CRP levels and PMS as early predictors of clinical and endoscopic outcomes in adult patients with moderately-to-severely active UC treated with tofacitinib: a post hoc analysis of OCTAVE Induction 1 and 2

ECCO'20 Vienna

Year: 2020
Authors:

M.C. Dubinsky1, D.P. Hudesman2, F. Steinwurz3, N. Kulisek4, L. Salese4, J. Paulissen5, C. Su4, D. Ponce de Leon6, F. Magro7

1Icahn School of Medicine at Mount Sinai, New York, New York, USA, 2New York University, New York, New York, USA, 3Unit of Inflammatory Bowel Disease, Hospital Israelita Albert Einstein, São Paulo, Brazil, 4Pfizer Inc., Collegeville, Pennsylvania, USA, 5Syneos Health, Morrisville, North Carolina, USA, 6Pfizer Inc., Lima, Peru, Peru, 7University of Porto and Centro Hospitalar São João, Porto, Portugal, Portugal

P367 Real-life long-term effectiveness and treatment persistence of vedolizumab in a single tertiary care cohort of Crohn’s disease patients

ECCO'20 Vienna

Year: 2020
Authors:

L. Calandrini, M. Salice, H. Privitera Hrustemovic, G. Peruzzi, F. Rizzello, C. Calabrese, E. Scaioli, A. Belluzzi, P. Gionchetti

Policlinico Sant’Orsola Malpighi, Malattie Infiammatorie Croniche Prof. Gionchetti, Bologna, Italy

P368 Tofacitinib induction efficiency and intracellular cytokine dynamics in ulcerative colitis: Results from clinical practice

ECCO'20 Vienna

Year: 2020
Authors:

M. Kolar1, M. Lukas1, K. Malickova1,2, L. Prochazkova1, M. Bortlik1,3,4, D. Duricova1, V. Hruba1, N. Machkova1, K. Mitrova1, M. Vasatko1, M. Lukas1,2

1ISCARE I.V.F. a.s., IBD Clinical and Research Centre, Prague, Czech Republic, 2Institute of Medical Biochemistry and Laboratory Medicine, General University Hospital and First Faculty of Medicine-Charles University, Prague, Czech Republic, 3Institute of Pharmacology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 4Department of Internal Medicine, First Faculty of Medicine, Charles University and Military University Hospital, Prague, Czech Republic

P369 Mycobacterium tuberculosis infection among patients with inflammatory bowel disease under biologics: experience of Croatian Tertiary Centre

ECCO'20 Vienna

Year: 2020
Authors:

D. Ogresta, A. Bišćanin, V. Tomašić, Z. Dorosulić, D. Kralj, J. Forgač, P. Ćaćić, I. Lerotić, D. Hrabar

Department of Gastroenterology and Hepatology, University Hospital Center Sestre milosrdnice, Zagreb, Croatia

P370 Endoscopic balloon dilatation in paediatric stricturing Crohn’s disease: A retrospective collaborative study of the paediatric IBD Porto group of ESPGHAN

ECCO'20 Vienna

Year: 2020
Authors:

O. Ledder1, J. Viala2, D. Urlep3, D. Serban4, L. De Ridder5, M. Martinelli6, C. Romano7, S. Oliva8, S. Sharma9, M. Thomson9, D. Turner1, Paediatric IBD Porto Group of ESPGHAN

1Department of Pediatric Gastroenterology and Nutrition, Shaare Zedek Medical Center, Jerusalem, Israel, 2Department of paediatric gastroenterology, Hôpitaux de Paris, Paris, France, 3Department of Paediatric Gastroenterology, Ljubljana University Medical Centre, Ljubljana, Slovenia, 4Emergency Clinical Hospital for Children, 2nd Clinic of Pediatrics, Cluj-Napoca, Romania, 5Department of Paediatric Gastroenterology, Erasmus MC/Sophia Children′s Hospital, Rotterdam, The Netherlands, 6Department of Translational Medical Science, Section of Pediatrics, University of Naples Federico II, Naples, Italy, 7Department of Paediatric Gastroenterology, University of Messina, Messina, Italy, 8Department of Paediatric Gastroenterology, Sapienza University of Rome, Rome, Italy, 9Department of Paediatric Gastroenterology, Sheffield Children’s Hospital, Sheffield, UK

P371 Self-medication with analgesics in ulcerative colitis: Results of a patient survey

ECCO'20 Vienna

Year: 2020
Authors:

I. Rodríguez-Lago1, F. Mesonero Gismeno2, M. Cañas3, C. Savini4, R. Saldaña4, L. Feo-Lucas5, S. Fernandez5, L. Cea-Calvo5, B. Juliá5

1Gastroenterology Department- IBD Unit, Hospital de Galdakao, Galdakao, Spain, 2Gastroenterology Department- IBD Unit, Hospital Ramón y Cajal, Madrid, Spain, 3Gastroenterology Department, Hospital Clínico San Carlos, Madrid, Spain, 4Spanish Confederation of Associations Of Patients with Crohn’s Disease and Ulcerative Colitis ACCU, ACCU, Madrid, Spain, 5Medical Affairs Department, Merck Sharp and Dohme of Spain, Madrid, Spain

P372 Effects of filgotinib on anaemia, thrombocytopenia and leukopenia: Phase 3 study results in patients with active rheumatoid arthritis and prior inadequate response/intolerance to biological DMARDs

ECCO'20 Vienna

Year: 2020
Authors:

R. Besuyen1, M. Genovese2, K. de Vlam3, J.E. Gottenberg4, K. Kalunian5, B. Bartok6, Y. Tan7, Y. Guo8, C. Tasset1, J. Sundy9, D. Walker10, T. Takeuchi11

1Galapagos NV, Clinical Development, Mechelen, Belgium, 2Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA, 3Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, 4Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 5Division of Rheumatology- Allergy and Immunology, University of California, San Diego, CA, USA, 6Medical Affairs, Gilead Sciences Inc., Foster City, CA, USA, 7Clinical Development, Gilead Sciences Inc., Foster City, CA, USA, 8Biostatistics, Gilead Sciences Inc., Foster City, CA, USA, 9Clinical Research, Gilead Sciences Inc., Foster City, CA, USA, 10Department of Rheumatology, Northumbria Healthcare, Northumbria, UK, 11Division of Rheumatology and Clinical Immunology, Keio University School of Medicine, Tokyo, Japan

P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project

ECCO'20 Vienna

Year: 2020
Authors:

K. Malickova1,2, V. Pesinova1, M. Bortlik1,3,4, D. Duricova1,3, N. Machkova1, V. Hruba1, M. Lukas1,5, K. Mitrova1,6, M. Vasatko1, M. Kostrejova1,7, M. Kolar1,5, M. Lukas1,2

1Clinical and Research Center for Inflammatory Bowel Disease, ISCARE a.s. and Charles University, Prague 7, Czech Republic, 2Institute of Medical Biochemistry and Lab Diagnostics, General University Hospital and 1st Faculty of Medicine, Prague, Czech Republic, 3Institute of Pharmacology, First Faculty of Medicine of Charles University, Prague, Czech Republic, 4Department of Internal Medicine, Military University Hospital and 1st Faculty of Medicine of Charles University, Prague, Czech Republic, 5Institute of Animal Physiology and Genetics, Czech Academy of Sciences, Libechov, Czech Republic, 6Department of Pediatry, University Hospital Motol and 2nd Faculty of Medicine of Charles University, Prague, Czech Republic, 7Department of Internal Medicine, Hospital of the Sisters of Mercy of St. Borromeo, Prague, Czech Republic

P374 Disease course and fate of Crohn’s perianal fistula patients following failure of initial biologic therapy: real-world lessons on the impact of refractory disease from a tertiary centre cohort

ECCO'20 Vienna

Year: 2020
Authors:

S. Adegbola, W.Y. Mak, K. Sahnan, S. Hiles, P. Bassett, P. Lung, J. Warusavitarne, O. Faiz, R. Phillips, P. Tozer, A. Hart

Department of Colorectal Surgery, St. Mark’s Hospital, Harrow, UK